U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C29H40O7
Molecular Weight 500.6237
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DESONIDE PIVALATE

SMILES

[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COC(=O)C(C)(C)C

InChI

InChIKey=FAPMGCFSVXGXMO-FHKBAQRKSA-N
InChI=1S/C29H40O7/c1-25(2,3)24(33)34-15-21(32)29-22(35-26(4,5)36-29)13-19-18-9-8-16-12-17(30)10-11-27(16,6)23(18)20(31)14-28(19,29)7/h10-12,18-20,22-23,31H,8-9,13-15H2,1-7H3/t18-,19-,20-,22+,23+,27-,28-,29+/m0/s1

HIDE SMILES / InChI

Molecular Formula C29H40O7
Molecular Weight 500.6237
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Desonide is a topical glucocorticoid which was approved by FDA for the treatment of such conditions as eczema, psoriasis, atopic dermatitis, etc. The exact mechanism of drug action is unknown.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DESONIDE

Approved Use

Desonide Ointment, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. It should not be used for longer than two weeks unless directed by a physician.

Launch Date

1972
Primary
DESONIDE

Approved Use

Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

Launch Date

1972
Primary
DESONIDE

Approved Use

Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

Launch Date

1972
Primary
DESONIDE

Approved Use

Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

Launch Date

1972
Primary
DESONIDE

Approved Use

Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

Launch Date

1972
Doses

Doses

DosePopulationAdverse events​
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.3
unhealthy
n = 425
Health Status: unhealthy
Condition: Atopic dermatitis
Population Size: 425
Sources: Page: p.3
Disc. AE: Telangiectasia...
AEs leading to
discontinuation/dose reduction:
Telangiectasia
Sources: Page: p.3
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atopic dermatitis
Sources: Page: p.1
Disc. AE: Cushing's syndrome, Hypothalamic pituitary adrenal axis suppression...
AEs leading to
discontinuation/dose reduction:
Cushing's syndrome
Hypothalamic pituitary adrenal axis suppression
Atrophy
Striae
Irritation skin
Acneiform eruption
Skin hypopigmentation
Allergic contact dermatitis
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Telangiectasia Disc. AE
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.3
unhealthy
n = 425
Health Status: unhealthy
Condition: Atopic dermatitis
Population Size: 425
Sources: Page: p.3
Acneiform eruption Disc. AE
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atopic dermatitis
Sources: Page: p.1
Allergic contact dermatitis Disc. AE
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atopic dermatitis
Sources: Page: p.1
Atrophy Disc. AE
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atopic dermatitis
Sources: Page: p.1
Cushing's syndrome Disc. AE
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atopic dermatitis
Sources: Page: p.1
Hypothalamic pituitary adrenal axis suppression Disc. AE
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atopic dermatitis
Sources: Page: p.1
Irritation skin Disc. AE
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atopic dermatitis
Sources: Page: p.1
Skin hypopigmentation Disc. AE
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atopic dermatitis
Sources: Page: p.1
Striae Disc. AE
0.05 % 2 times / day multiple, topical
Recommended
Dose: 0.05 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.05 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Atopic dermatitis
Sources: Page: p.1
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes (co-administration study)
Comment: Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide. If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered
Page: 4,8
PubMed

PubMed

TitleDatePubMed
Overview on desonide 0.05%: a clinical safety profile.
2004 Jul-Aug
Two case reports of cutaneous adverse reactions following hepatitis B vaccine: lichen planus and granuloma annulare.
2004 Sep
Efficacy of desonide 0.05% cream and lotion in steroid-responsive dermatoses in Indian patients: a post-marketing surveillance study.
2004 Sep-Oct
Comparison of the analysis of corticosteroids using different techniques.
2005 Jan
Erythematous scaling eyelids: patient history, exposure to allergens and irritants are keys to diagnosis.
2005 Jun
Rapid resolution of a common problem.
2005 May
Desonide foam 0.05%: safety in children as young as 3 months.
2008 Aug
Desonide: a review of formulations, efficacy and safety.
2008 Jul
Worrisome perioral rash on a young boy. Lip-licker's dermatitis.
2008 May
Manifestations of cutaneous sarcoidosis: a case report of an African American woman.
2009 Jun
Generic sample preparation combined with high-resolution liquid chromatography-time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories.
2010 Apr
Update on the management of chronic eczema: new approaches and emerging treatment options.
2010 Jul 28
Patents

Sample Use Guides

Desonide Cream, 0.05% should be applied to the affected area as a thin film two to four times daily depending on the severity of the condition.
Route of Administration: Topical
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 10:07:00 GMT 2023
Edited
by admin
on Sat Dec 16 10:07:00 GMT 2023
Record UNII
UB3LO24HGK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DESONIDE PIVALATE
WHO-DD  
Common Name English
PREGNA-1,4-DIENE-3,20-DIONE, 21-(2,2-DIMETHYL-1-OXOPROPOXY)-11-HYDROXY-16,17-((1-METHYLETHYLIDENE)BIS(OXY))-, (11.BETA.,16.ALPHA.)-
Systematic Name English
Desonide pivalate [WHO-DD]
Common Name English
Code System Code Type Description
SMS_ID
300000034982
Created by admin on Sat Dec 16 10:07:00 GMT 2023 , Edited by admin on Sat Dec 16 10:07:00 GMT 2023
PRIMARY
FDA UNII
UB3LO24HGK
Created by admin on Sat Dec 16 10:07:00 GMT 2023 , Edited by admin on Sat Dec 16 10:07:00 GMT 2023
PRIMARY
EPA CompTox
DTXSID00229315
Created by admin on Sat Dec 16 10:07:00 GMT 2023 , Edited by admin on Sat Dec 16 10:07:00 GMT 2023
PRIMARY
PUBCHEM
71300443
Created by admin on Sat Dec 16 10:07:00 GMT 2023 , Edited by admin on Sat Dec 16 10:07:00 GMT 2023
PRIMARY
CAS
78806-68-5
Created by admin on Sat Dec 16 10:07:00 GMT 2023 , Edited by admin on Sat Dec 16 10:07:00 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY